Two new appointments at AAIPharma
This article was originally published in Scrip
AAIPharma (US) has appointed Dr Andreas Dreps senior vice-president of global clinical development services and Dr Ralf Wolter vice-president of clinical operations – Europe. Dr Dreps has more than 15 years' drug development experience, most recently leading the oncology therapeutic area at ICON. He has also worked at Merck KGaA, Rhône-Poulenc Rorer/Aventis and Bristol Myers-Squibb. Dr Wolter previously served as vice-president of clinical development at Apogenix, a German biotech company focused on oncology.
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.
Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.